Strategic Research Funding : A Success Story for Medical Mycology by Gow, Neil A R et al.
Science & Society
Strategic Research
Funding: A Success
Story for Medical
Mycology
[77_TD$DIFF]Neil A.R. Gow,1,*
Tehmina Amin,1 Karen McArdle,1
Alistair J.P. Brown,1
Gordon D. Brown,1
Adilia Warris,1 and
the WTSA-MMFI Consortium2
The Wellcome Trust Strategic
Award in Medical Mycology and
Fungal Immunology is a unique
investment that aimed to bolster
capacity, training and research
activity throughout the UK. This
article summarises the rationale
for collective collaboration of
multiple institutions to achieve
synergies and address a common
medical problem.
Background about Fungal
Infections
Medical mycology is one of many areas in
the biomedical sciences that is served by a
small, dispersed community that is below
critical mass. Whilst funders may be sym-
pathetic to the challenges in stimulating
growth and research activity in such areas,
they may lack appropriate fundingmecha-
nisms to create synergies and draw
research communities together. This arti-
cle reports on the outputs and achieve-
ments of a Wellcome Trust Strategic
Award in Medical Mycology and Fungal
Immunology (WTSA-MMFI)i[79_TD$DIFF] (Figure 1) that
links 13 institutions to build capacity in the
ﬁeld, stimulate interdisciplinary research
[80_TD$DIFF]and train a new generation of researchers
in the UK and in low- and middle-income
countries (LMIC[81_TD$DIFF]).
Fungi are critical to the function of the
world’s ecosystem, and many species
provide vital chemicals, drugs [82_TD$DIFF]and food
products. As model systems, fungi have
been the organisms of choice for a dozen
Nobel laureates to illustrate fundamental
principles in genetics and cell biology.
Some fungi are known for their ability
to cause skin infections (ringworm, ath-
lete’s foot, dandruff etc.), whereas others
are a feared cause of fatal human infec-
tions [1]. Deaths per annum due to fungal
infections are greater than the global
mortality due to malaria, breast or pros-
tate cancer, and are similar to that
inﬂicted by tuberculosis (TB) or HIV [2]ii.
A systematic analysis of the fungal dis-
ease burden in 2017, covering 883 mil-
lion people in 14 countries, revealed that
an average of 2% of people have a seri-
ous fungal infection [3]. In many of these
countries, the ﬁgures can only be esti-
mates, due to inadequate or late diagno-
sis and a lack of effective reporting
systems, suggesting a signiﬁcantly
higher actual burden. Current global esti-
mates suggest that over a million people
die of fungal infections, 10 million suffer
severe fungal allergy, 100 million women
are victims of recurrent vulvovaginal
infections annually, and more than a bil-
lion people suffer skin infections [2]ii.
There are no vaccines or immunothera-
pies for mycoses and only a limited arse-
nal of antifungal drugs to treat infections,
with invasive infections often diagnosed
too late to save the patient.
Building Critical Mass
In the UK, between 1997 and 2010, total
investment in all infectious disease
research was £2.6 billion [4], but only
2% of this was spent on medical mycol-
ogy research [5]. A strategic MRC review
in London in 2014iii [83_TD$DIFF] indicated that this
reﬂected the small number of applications
submitted, rather than a low funding suc-
cess rate. This situation was reﬂected in
other European countries and in the USA.
The UK mycology research community is
small, comprising fewer than 60 principal
investigators (basic scientists or clinical
academics). There are three established
clinical mycology reference centres
(Bristol, Manchester [84_TD$DIFF]and Leeds) and only
around ten medical mycology specialist
clinicians serving the whole UK popula-
tion. Only [85_TD$DIFF]eight small/medium enterprises
(SMEs) are engaged inmedical mycology,
and there are two major specialist
research centres: the MRC Centre for
Medical Mycology at Aberdeen and the
Manchester Fungal Infection Group and
National Aspergillosis Centre at Man-
chester. National mycological training is
mainly provided by the British Society for
Medical Mycology (BSMM) Masters level
course and Public Health England (PHE)
at the Bristol Mycology Reference Labo-
ratory. However, it has been recognised
by both Wellcome and the MRC that
capacity in the UK is suboptimal and that
signiﬁcant investment is required to bring
critical mass to the sector. In addition, the
true burden of serious fungal disease falls
hardest on areas of high endemic disease
in LMIC – many of which have little local
expertise.
In 2011 the Aberdeen Fungal Group
(AFG) was successful in securing a
£5.1 million WTSA award to establish
and direct the MMFI consortium to
address these problems. The AFG,
based at the University of Aberdeen, is
now the home of the MRC Centre for
Medical Mycology – a world-renowned
multidisciplinary research group at the
forefront of medical research into myco-
ses with expertise encompassing basic
molecular biology and immunology
through to clinical research. Between
1997 and 2010 the AFG had received
£16.9 m (35%) of all medical mycology
funding awarded in the UK [5]. By 2015,
the MMFI consortium had grown to
include the Universities of Birmingham,
Exeter, Glasgow, Kent, Liverpool, Man-
chester, Newcastle, Shefﬁeld, Imperial
and King’s Colleges and St George’s
University in London.
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The overarching rationale of the WTSA-
MMFIwastoharnessthecollectiveresearch
capacity in the UK community to undertake
cross-institutional interdisciplinary research
and training that could help develop capac-
ity in the UK whilst simultaneously address-
ing problems in countries with the greatest
fungal disease burden. Therefore, the con-
sortium funded a cohort of 12 international
PhD studentships from LMIC: Cameroon,
Colombia, India (2), Malawi (2), Mexico,
Nigeria, South Africa, Uganda (2) [86_TD$DIFF]and
Uruguay, as well as 3 clinical PhDs and 6
postdoctoral fellowships (from the UK/EU).
Most of the funded posts were supported
by new cross-institutional partnerships. In
addition, one clinical academic in medical
mycology was recruited to the UK.
Thespeciﬁcaimsof theconsortiumwere: (i)
to promote research excellence and new
interdisciplinary scientiﬁc initiatives in
medicalmycologyand fungal immunology;
(ii) to integrate, expand and resource com-
plementary skills in the ﬁeld, thereby
increasingunderstandingof fungal disease
and translating basic research into the
clinic and pharmaceutical industry; (iii) to
establish a national consortium to coordi-
nate a research and training programme
that harnesses the excellent, but dis-
persed, expertise within the UK to under-
stand and treat fungal infections and to
train a new generation of scientists [87_TD$DIFF]and
(iv) to promote the public understanding
and proﬁle of this often misrepresented
and underappreciated area of science.
International student recruitmentwas sup-
ported by LMIC academic leaders who
maintained engagement in the students’
UK-based training and, upon successful
completion of the training programme,
facilitated their redeployment into jobs in
their home countries. The students all
undertook an MRes degree at the Univer-
sity of Aberdeen to provide basic expertise
in medical mycology, molecular biology
[88_TD$DIFF]and immunology, before selecting a uni-
versity within theUK to complete their PhD
training. All projects offered to the MRes/
PhD students, postdoctoral researchers
[89_TD$DIFF]and clinical fellowswere vetted by an Inter-
national Advisory Board and local
Management Board for excellence and
alignment against strategic priorities. All
trainees met annually at meetings of the
BSMM to present their research, and
attended courses in careers, scientiﬁc
paper and grant writing, fellowship appli-
cations, research commercialisation, and
other generic skills. All students also
attended a workshop on fungal diagnos-
tics and epidemiology hosted by Dr Eliz-
abeth Johnson and colleagues at PHE in
Bristol, and information sessions hosted
by Wellcome on funding opportunities rel-
evant to their future careers. The students
therefore beneﬁted from the collective
expertise available throughout the MMFI
consortium and from the building of a
vibrant network of colleagues and exper-
tise that extended across the whole UK
sector. TheMMFI consortium alsoworked
alongside other Wellcome-funded infec-
tious disease centres in Dundee, Glasgow
[90_TD$DIFF]and Edinburgh to present showcase
events foreukaryoticmedicalmicrobiology
that led to cross-disciplinary analyses, for
example, drug resistance in eukaryotic
pathogens [6].
Outputs and Impact
Since 2012 the consortium has gener-
ated more than 250 communications
(talks, posters, workshops, videos, pod-
casts [91_TD$DIFF]and press articles) and 120
research publications in high-impact jour-
nals, including Nature, Science, Nature
Immunology, Nature Microbiology, Jour-
nal of Experimental Medicine, PLoS
Pathogens, mBio, PNAS [92_TD$DIFF]and Molecular
Microbiology. In addition, the WTSA-
MMFI has supported numerous public
engagement activities across the UK. A
major exhibition entitled ‘Killer Fungus’
was held at the Royal Society Summer
Science Exhibition in London in 2016.
This exhibition, involving 80 consortium
members, attracted over 14 000 visitors.
A further exhibition ‘Killer Fungus Out-
break’ took place at the Manchester Sci-
ence Festival in 2017, and an extended
exhibit ‘The Kingdom of Fungi’ was
established at the Aberdeen Science
Centre in 2016 and is still running. Many
smaller scale public engagement events
were also held by members of the con-
sortium, leading to world-wide coverage
by the BBC, CNN [93_TD$DIFF]and major newspapers
and magazines. The Killer Fungus public
engagement brand created movie clips,
apps [94_TD$DIFF]and games (including the Killer Fun-
gus Evolution and Fungal Invaders
games) that are freely available to inform
the public of medical mycology issuesiv.
The WTSA-MMFI was conceived as a
unique approach to tackling the major
global impact of invasive fungal infection
by harnessing collective medical mycol-
ogy expertise in the UK to create syner-
gies in research and training activities. As
a result, the UK medical mycology
research community has become more
ﬁrmly integrated. Capacity in this critical
sector has grown, and public awareness
of medical mycology issues has
increased. Invasive fungal infections con-
tinue to rise, and organisations such as
GAFFIv and LIFEvi help to lever funds and
enhance global surveillance efforts and
promote the availability of key antifungals
in LMIC. However, new problems are aris-
ing. Antifungal resistance due to the
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Figure 1. Logo of WTSA-MMFI.
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agricultural use of azoles may be exacer-
bating the spread of drug-resistant
Aspergillus species, and emerging
multidrug-resistant species, such as
Candida auris, are fast becoming major
health threats [6–8]. These factors
emphasise the need for high-quality med-
ical mycology research, with strategic and
targeted modes of funding, to enable
capacity development and research inter-
actions to counter these global threats.
Resources
iwww.abdn.ac.uk/mmﬁ/
iihttps://microbiologysociety.org/uploads/assets/
uploaded/
fe85786a-df67-48de-a60982800c1a0829.pdf
iiihttps://mrc.ukri.org/documents/pdf/
fungal-disease-research-workshop-report/
ivwww.killerfungus.org/
vwww.gafﬁ.org/
viwww.life-worldwide.org/
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Mycobacterium tuberculosis inter-
feres with the ability of its host cell
to undergo apoptosis. Arnett et al.
report that the pathogen promotes
macrophage survival by engaging
the nuclear receptor PPARg to
induce the antiapoptotic protein
MCL-1, yielding insights into the
pathogenesis of tuberculosis and
potentially unlocking new avenues
for therapeutic intervention.
Many of the most signiﬁcant pathogens of
humans and animals adopt at least a
partially intracellular lifestyle in order to
persist and cause disease. Apoptosis is
a programmed cell death pathway
thought to have evolved primarily as a
defense against such intracellular patho-
gens [1]. Eliminating infected cells via
apoptosis not only strips the pathogen
of its intracellular replicative niche but
can also directly kill the pathogen as well
as stimulate adaptive immune responses
[2]. For some pathogens, such as
M. tuberculosis, the ability to subvert this
altruistic host cell death is essential for
their persistence. Indeed, the extent of
macrophage apoptosis upon infection
with different strains of M. tuberculosis
has been inversely correlated with
virulence, although there remains little
consensus in terms of exactly how
M. tuberculosis curbs apoptosis of its
primary host cell. Nonetheless, several
reports have reproducibly implicated the
rapid and sustained upregulation of
MCL-1 in infected macrophages as a
key restriction factor for apoptosis, and
therefore, for mycobacterial control [3,4].
MCL-1 is an antiapoptotic member of the
BCL-2 protein family, which regulates the
intrinsic pathway of apoptosis through
interactions between its pro- and antia-
poptotic constituents [5]. Until recently,
mechanistic insights intoMcl-1 regulation
during M. tuberculosis infection have
been lacking.
Arnett et al. [6] set out to identify effectors
downstream of peroxisome proliferator-
activated receptor (PPAR)g – a nuclear
receptor and transcription factor which
is highly induced in alveolar macrophages
infected with M. tuberculosis. Activation
of PPARg is known to promote intracel-
lular growth of the pathogen, although the
transcriptional changes leading to this
enhanced growth had previously
remained unclear. The authors performed
gene expression analysis of human
macrophages infected withM. tuberculo-
sis, revealing a number of genes that are
differentially regulated upon PPARg
knockdown, including Mcl-1, which is
signiﬁcantly downregulated [6]. This
demonstrates that PPARg promotes
Mcl-1 expression, thus establishing a
potently antiapoptotic cellular milieu.
Mechanistically, PPARg expression is
induced upon recognition of mannosy-
lated lipoarabinomannan present in the
cell wall of M. tuberculosis and is acti-
vated by lipid agonists generated by the
host enzyme 15-lipoxygenase [6]. Acti-
vated PPARg then binds to genetic
elements within the Mcl-1 promoter to
enhance transcription. Knockdown of
either PPARg or MCL-1 was shown to
promote a modest increase in the death
of infected macrophages, highlighting the
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